For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies. Dr. Srivastava discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally, with artificial intelligence, automation, and new robotic platforms remaining central to the company’s long-term product roadmap. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery.
The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets. Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses.
This announcement underscores the growing importance of cost-effective robotic surgery solutions in global healthcare. By focusing on affordability and remote capabilities, SS Innovations aims to democratize access to advanced surgical technologies, potentially transforming surgical care in underserved regions. The company's progress, including over 200 installations and nearly 12,000 procedures, demonstrates market validation of its approach. As regulatory approvals advance, the implications for surgical robotics adoption could be significant, particularly in emerging markets where cost barriers have limited access.
For more details on the interview, visit the original release. Investors should review the full terms of use and disclaimers on the InvestorBrandNetwork website.
